Streetbeat News

Analyst Ratings

PRDO

Barrington Research analyst Alexander Paris has reiterated an Outperform rating on Perdoceo Education (NASDAQ:PRDO) and maintained a $23 price target.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 7:37 pm

OMCL

Benchmark analyst Bill Sutherland maintains a Buy rating on Omnicell (NASDAQ:OMCL) but lowers the price target from $42 to $38.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 7:34 pm

LTRX

Roth MKM analyst Scott Searle maintains a Buy rating on Lantronix (LTRX) but lowers the price target from $12 to $9.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 7:32 pm

POWI

Benchmark analyst David Williams maintains a Buy rating on Power Integrations (NASDAQ:POWI) and raises the price target from $80 to $90.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 7:31 pm

MKSI

Benchmark analyst Mark Miller maintains a Buy rating on MKS Instruments (NASDAQ:MKSI) and raises the price target from $85 to $130, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 7:28 pm

ONTO

Benchmark analyst Mark Miller maintains a Buy rating on Onto Innovation (NYSE:ONTO) and raises the price target from $145 to $180.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 7:25 pm

ALC

BLCO

Bausch + Lomb Corp (BLCO) is set to report its Q4 and full-year 2023 financial results on February 21, 2024, with expected sales of $1.107 billion and EPS of $0.17. RBC Capital predicts Q4 revenue of $1.159 billion and adjusted EBITDA of $224 million, slightly below consensus. The company anticipates improved EBITDA margins in 2024, following the Xiidra acquisition. RBC forecasts FY 2024 sales of $4.72 billion, a 14% increase year-over-year. Alcon Inc (ALC) announced Phase 3 data for its dry-eye product, planning a New Drug Application in mid-2024, highlighting a competitive market for dry-eye products in 2025. RBC lowered BLCO's price target from $20 to $19 but maintained an Outperform rating.

Portfolio Pulse from Vandana Singh

February 09, 2024 | 7:24 pm

PINS

Roth MKM analyst Rohit Kulkarni has maintained a Neutral rating on Pinterest (PINS) and increased the price target from $37 to $38.

Portfolio Pulse from Benzinga Newsdesk

February 09, 2024 | 7:21 pm

NET

Cloudflare Inc (NYSE:NET) reported strong Q4 results, surpassing FactSet consensus estimates on key financial metrics and signaling robust growth ahead. Analysts from various firms have raised their price targets for NET, reflecting optimism about the company's future performance. The stock surged over 20% following the announcement. Key highlights include the signing of Cloudflare's most significant new logo and customer renewal, improved sales force productivity, and guidance for 2024 indicating a 27% Y/Y revenue growth and an FCF margin of ~10%.

Portfolio Pulse from Anusuya Lahiri

February 09, 2024 | 7:21 pm

IGMS

RBC Capital upgraded IGM Biosciences Inc (NASDAQ:IGMS), a biotech company focusing on antibody medicines for cancer, to Outperform from Sector Perform with a new price target of $21, up $9. The upgrade is based on IGM Biosciences' strategic shift of imvotamab from non-Hodgkin’s lymphoma to immunology, leveraging its safety and efficacy for autoimmune diseases. This positions imvotamab as a promising off-the-shelf treatment. The company anticipates data in the second half of 2024 to further validate this approach, seeing it as a long-term opportunity exceeding $1 billion. IGMS shares are up 12.3% at $14.54.

Portfolio Pulse from Vandana Singh

February 09, 2024 | 7:16 pm